The nation’s potential fourth vaccine option proved a 90.4 percent efficacy rate against COVID-19 among adults and 80 percent efficacy among study participants 12 to 17 years old in phase 3 trials, according to the company’s press release.
On June 7, an independent FDA panel voted 21-0, with one absentee, to recommend Novavax’s vaccine for emergency use authorization for adults.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
